PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25501281-4 2015 Hexokinase and CPT-1 activities were examined in the presence of different concentrations of their inhibitors, lonidamine and etomoxir, to find the concentration of maximum inhibition ([I max]). etomoxir 126-134 carnitine palmitoyltransferase 1A Homo sapiens 15-20 25501281-9 2015 Hexokinase and CPT-1 activities were significantly inhibited by lonidamine [600 muM] and etomoxir [100 muM] in both cell lines. etomoxir 89-97 carnitine palmitoyltransferase 1A Homo sapiens 15-20 25122071-5 2014 Etomoxir is an irreversible inhibitor of the carnitine palmitoyltransferase (CPT1) enzyme that decreases beta oxidation in the mitochondria. etomoxir 0-8 carnitine palmitoyltransferase 1A Homo sapiens 77-81 25122071-8 2014 Knockdown of CPT1A enzyme in LNCaP cells resulted in decreased palmitate oxidation but increased sensitivity to etomoxir, with inactivation of AKT kinase and activation of caspase-3. etomoxir 112-120 carnitine palmitoyltransferase 1A Homo sapiens 13-18 21745359-7 2011 When CPT1-inhibitor etomoxir was included during culture at low glucose palmitate-triggered apoptosis was accentuated both in the islets and the cell lines. etomoxir 20-28 carnitine palmitoyltransferase 1A Homo sapiens 5-9 24488024-8 2014 Pharmacological inhibition of FAO with etomoxir recapitulated the CPT1A KD phenotype. etomoxir 39-47 carnitine palmitoyltransferase 1A Homo sapiens 66-71 17319797-1 2007 Etomoxir is an inhibitor of mitochondrial CPT1 (carnitine palmitoyltransferase 1) and thereby switches energy metabolism from fatty acids to glucose oxidation. etomoxir 0-8 carnitine palmitoyltransferase 1A Homo sapiens 42-46 20820848-4 2011 Inhibiting DGAT or CPT-1 by using, respectively, amidepsine or etomoxir increased DAG accumulation and sensitized myotubes to palmitate-induced insulin resistance. etomoxir 63-71 carnitine palmitoyltransferase 1A Homo sapiens 19-24 17319797-1 2007 Etomoxir is an inhibitor of mitochondrial CPT1 (carnitine palmitoyltransferase 1) and thereby switches energy metabolism from fatty acids to glucose oxidation. etomoxir 0-8 carnitine palmitoyltransferase 1A Homo sapiens 48-80 11866664-8 2002 Regarding the possible direct action of etomoxir on peroxisome proliferator activated receptor alpha (PPAR-alpha) activation, it could upregulate the expression of various enzymes that participate in beta-oxidation, thereby modulating some effects of CPT 1 inhibition. etomoxir 40-48 carnitine palmitoyltransferase 1A Homo sapiens 251-256 12075114-1 2002 Although they are known to be effective antidiabetic agents, little is published about the toxic effects of carnitine palmitoyltransferase-1 (CPT-1) inhibitors, such as etomoxir (ET). etomoxir 179-181 carnitine palmitoyltransferase 1A Homo sapiens 142-147 17149674-2 2006 Lead compounds for correcting a dysregulated gene expression are the carnitine palmitoyltransferase-1 (CPT-1) inhibitors etomoxir and oxfenicine. etomoxir 121-129 carnitine palmitoyltransferase 1A Homo sapiens 69-101 17149674-2 2006 Lead compounds for correcting a dysregulated gene expression are the carnitine palmitoyltransferase-1 (CPT-1) inhibitors etomoxir and oxfenicine. etomoxir 121-129 carnitine palmitoyltransferase 1A Homo sapiens 103-108 16777940-6 2006 Accordingly, pharmacological inhibition of CPT1 by etomoxir restored the effects of oleic acid under low glucose conditions. etomoxir 51-59 carnitine palmitoyltransferase 1A Homo sapiens 43-47 16225603-7 2005 Etomoxir was able to block CPT-1 activity in skin, implying that this antagonist may have the potential to suppress psoriasis when administered topically. etomoxir 0-8 carnitine palmitoyltransferase 1A Homo sapiens 27-32 31555131-8 2019 CSE-induced apoptosis was further increased when cells were treated with a specific Cpt1 inhibitor etomoxir or transfected with Cpt1a siRNA. etomoxir 99-107 carnitine palmitoyltransferase 1A Homo sapiens 84-88 34650679-5 2021 Cotreatment with etomoxir, a specific inhibitor of carnitine palmitoyltransferase-1alpha (CPT-1alpha) activity, or CPT-1alpha siRNA abrogated ZLN005-induced antistress responses by mitigating reactive oxygen species production and decreasing apoptosis under ischemia-hypoxia conditions by suppressing MitoFAO. etomoxir 17-25 carnitine palmitoyltransferase 1A Homo sapiens 51-88 34213835-5 2021 Silencing CPT1A by siRNA or etomoxir, a specific small-molecule inhibitor of CPT1A, could reverse the sensitivity of drug-resistant colon cancer cells to oxaliplatin. etomoxir 28-36 carnitine palmitoyltransferase 1A Homo sapiens 77-82 34650679-5 2021 Cotreatment with etomoxir, a specific inhibitor of carnitine palmitoyltransferase-1alpha (CPT-1alpha) activity, or CPT-1alpha siRNA abrogated ZLN005-induced antistress responses by mitigating reactive oxygen species production and decreasing apoptosis under ischemia-hypoxia conditions by suppressing MitoFAO. etomoxir 17-25 carnitine palmitoyltransferase 1A Homo sapiens 90-100 34052835-7 2021 Simultaneously targeting SOAT1 and CPT1A by the small-molecule inhibitors avasimibe and etomoxir had synergistic anticancer efficacy in HCC in vitro and in vivo. etomoxir 88-96 carnitine palmitoyltransferase 1A Homo sapiens 35-40 34167568-6 2021 HepG2 cells pretreated with the CPT1 inhibitor etomoxir were treated with or without carnitine for 24 h. Next, the above indicators were examined, and apoptotic cells were analyzed via flow cytometry. etomoxir 47-55 carnitine palmitoyltransferase 1A Homo sapiens 32-36 34167568-11 2021 Inhibition of CPT1 activity with etomoxir induced hepatocyte injuries similar to those in burn patients and burned rats; carnitine supplementation restored CPT1 activity and ameliorated these injuries. etomoxir 33-41 carnitine palmitoyltransferase 1A Homo sapiens 14-18 34167568-11 2021 Inhibition of CPT1 activity with etomoxir induced hepatocyte injuries similar to those in burn patients and burned rats; carnitine supplementation restored CPT1 activity and ameliorated these injuries. etomoxir 33-41 carnitine palmitoyltransferase 1A Homo sapiens 156-160 32654140-7 2021 Inhibition of carnitine transport by chemotherapeutics, such as vinorelbine and vincristine, led to inhibition of FAO, which was further intensified by etomoxir - a CPT1 inhibitor. etomoxir 152-160 carnitine palmitoyltransferase 1A Homo sapiens 165-169 31776920-3 2020 However, studies demonstrating a role for LCFAO in memory T-cell development have largely relied on the use of etomoxir (ETO), a small molecule inhibitor of the long-chain fatty acid transporter CPT1A. etomoxir 111-119 carnitine palmitoyltransferase 1A Homo sapiens 195-200 31776920-3 2020 However, studies demonstrating a role for LCFAO in memory T-cell development have largely relied on the use of etomoxir (ETO), a small molecule inhibitor of the long-chain fatty acid transporter CPT1A. etomoxir 121-124 carnitine palmitoyltransferase 1A Homo sapiens 195-200 30175155-7 2018 Also, etomoxir and radiation combination treatment reduced the protein level of biomarkers for proliferation (Ki-67 and cyclin D1), stemness (CD44) and beta-oxidation (CPT1A) in H460 spheres. etomoxir 6-14 carnitine palmitoyltransferase 1A Homo sapiens 168-173 30282046-1 2018 Previous immunometabolism research using the CPT1 inhibitor etomoxir suggests that long-chain fatty acid oxidation (LC-FAO) supports IL-4-driven alternative macrophage activation (M(IL-4)) and regulates memory and regulatory T cell formation. etomoxir 60-68 carnitine palmitoyltransferase 1A Homo sapiens 45-49 30043752-4 2018 Unexpectedly, high concentrations of etomoxir retained the ability to disrupt M(IL-4) polarization in the absence of Cpt1a or Cpt2 expression. etomoxir 37-45 carnitine palmitoyltransferase 1A Homo sapiens 117-122 30043753-3 2018 However, evidence for this is mostly based on inhibition of Cpt1a, the rate-limiting enzyme for LC-FAO, with the drug etomoxir. etomoxir 118-126 carnitine palmitoyltransferase 1A Homo sapiens 60-65 29721083-9 2018 Either RNA interference or pharmacological blockade by Etomoxir were used to inhibit CPT1A. etomoxir 55-63 carnitine palmitoyltransferase 1A Homo sapiens 85-90 29754287-14 2018 Pharmacological inhibition of AMP-activated protein kinase and etomoxir, an inhibitor of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme in fatty acid beta-oxidation, attenuated the protective effect of the ELOVL2/DHA axis during glucolipotoxicity. etomoxir 63-71 carnitine palmitoyltransferase 1A Homo sapiens 89-121 29754287-14 2018 Pharmacological inhibition of AMP-activated protein kinase and etomoxir, an inhibitor of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme in fatty acid beta-oxidation, attenuated the protective effect of the ELOVL2/DHA axis during glucolipotoxicity. etomoxir 63-71 carnitine palmitoyltransferase 1A Homo sapiens 123-127 29674640-0 2018 The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. etomoxir 21-29 carnitine palmitoyltransferase 1A Homo sapiens 4-9 29674640-1 2018 Etomoxir (ETO) is a widely used small-molecule inhibitor of fatty acid oxidation (FAO) through its irreversible inhibitory effects on the carnitine palmitoyl-transferase 1a (CPT1a). etomoxir 0-8 carnitine palmitoyltransferase 1A Homo sapiens 138-172 29674640-1 2018 Etomoxir (ETO) is a widely used small-molecule inhibitor of fatty acid oxidation (FAO) through its irreversible inhibitory effects on the carnitine palmitoyl-transferase 1a (CPT1a). etomoxir 0-8 carnitine palmitoyltransferase 1A Homo sapiens 174-179 29674640-1 2018 Etomoxir (ETO) is a widely used small-molecule inhibitor of fatty acid oxidation (FAO) through its irreversible inhibitory effects on the carnitine palmitoyl-transferase 1a (CPT1a). etomoxir 10-13 carnitine palmitoyltransferase 1A Homo sapiens 138-172 29674640-1 2018 Etomoxir (ETO) is a widely used small-molecule inhibitor of fatty acid oxidation (FAO) through its irreversible inhibitory effects on the carnitine palmitoyl-transferase 1a (CPT1a). etomoxir 10-13 carnitine palmitoyltransferase 1A Homo sapiens 174-179 29674640-5 2018 Using an shRNA approach to reduce CPT1a in T cells, we further demonstrate that the inhibition of oxidative metabolism in T cells by ETO is independent of its effects on FAO at concentrations exceeding 5 muM. etomoxir 133-136 carnitine palmitoyltransferase 1A Homo sapiens 34-39 29596410-2 2018 Here we show that when FAO was reduced approximately 90% by pharmacological inhibition of carnitine palmitoyltransferase I (CPT1) with low concentrations of etomoxir, the proliferation rate of various cancer cells was unaffected. etomoxir 157-165 carnitine palmitoyltransferase 1A Homo sapiens 124-128 29596410-5 2018 Moreover, CPT1 knockdowns had altered mitochondrial morphology and impaired mitochondrial coupling, whereas cells in which CPT1 had been approximately 90% inhibited by etomoxir did not. etomoxir 168-176 carnitine palmitoyltransferase 1A Homo sapiens 123-127 29528039-4 2018 MATERIAL AND METHODS Human kidney proximal tubular epithelial cell line (HK-2) cells were treated with PA, BBR, and/or palmitoyltransferase 1A (CPT1A) inhibitor Etomoxir. etomoxir 161-169 carnitine palmitoyltransferase 1A Homo sapiens 144-149 29528039-10 2018 Moreover, the CPT1A inhibitor Etomoxir counteracted the protective effect of BBR in TECs. etomoxir 30-38 carnitine palmitoyltransferase 1A Homo sapiens 14-19 27739027-5 2016 Further investigation showed that CPT-1a inhibitor etomoxir (ETO) can restore the sensitivity of PDAC cells to gemcitabine and regress xenograft tumors in vivo. etomoxir 51-59 carnitine palmitoyltransferase 1A Homo sapiens 34-40 27739027-5 2016 Further investigation showed that CPT-1a inhibitor etomoxir (ETO) can restore the sensitivity of PDAC cells to gemcitabine and regress xenograft tumors in vivo. etomoxir 61-64 carnitine palmitoyltransferase 1A Homo sapiens 34-40